… Today, The Michael J. Fox Foundation (MJFF) and the … unification builds on the strengths of both organizations, combining MJFF’s research expertise and PAN’s extensive … funding is cut. We can’t bring new drugs to market if they get stuck in complicated regulatory approvals. And we won’t …

… protein leucine-rich repeat kinase 2, or LRRK2 , is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of … abnormal LRRK2 activity that might lead to disease, and how drugs are affecting this abnormal activity.   Here’s …

… Sanofi-aventis has identified Nurr1 receptor agonists whose in vitro pharmacological activity, … disease-modifying therapy for Parkinson’s disease (PD). However, we have not yet been able to show clear in vivo … a novel disease modifying therapy for PD. Anticipated Outcome:  Positive results will reinforce the importance of …

… 092017_MJFF_BIOMARKERS-FINDING_TEST.pdf …

… father lived with. Inspired by his father's positivity and commitment to staying active throughout the disease, Bill set out to … as fast as you used to, modify your expectations and adjust how you train. Add more recovery between hard workouts -- …